PLEASANTON, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it will be participating in the Third Annual Canaccord Cardiovascular Conference on Tuesday, November 10.
The presentation by Gary F. Burbach, president and chief executive officer, will begin at 8 a.m., Pacific Standard Time (11 a.m., Eastern Standard Time).
The presentation will be available through the conference website at http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2843940 and via the company's website at www.thoratec.com
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec® VAD (Ventricular Assist Device) and HeartMate® LVAS (Left Ventricular Assist System), with more than 14,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) Division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's websites at http://www.thoratec.com or http://www.itcmed.com.
SOURCE Thoratec Corporation
|SOURCE Thoratec Corporation|
Copyright©2009 PR Newswire.
All rights reserved